COMMUNIQUÉS West-GlobeNewswire

RAMSAY SANTE : annual results at the end of June 2025
17/10/2025
PRESS RELEASE Paris, 17 th October 2025 Annual results at the end of June 2025 Revenue growth of 4.7% and Group EBITDA up 1.7% despite reduction in public funding; secured long term financing framework Activity growth [...]
RAMSAY SANTE : résultats annuels à fin juin 2025
17/10/2025
COMMUNIQUÉ DE PRESSE Paris, le 17 octobre 2025 Résultats annuels à fin juin 2025 Croissance du chiffre d'affaires de 4,7 % et EBITDA en hausse de 1,7 % malgré une baisse du financement public ; structure de financement [...]
Valitor Appoints Biotech and Ophthalmic Industry Veteran Gregory D. Kunst as Chief Executive Officer
17/10/2025
BERKELEY, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced the appointment of Gregory D. Kunst as chief executive officer [...]
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
17/10/2025
Company announcement – No. 22 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, October 17, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a [...]
Silver Creek Pharmaceuticals Receives FDA Fast Track Designation for Scp776 in Acute Ischemic Stroke
17/10/2025
Novel mechanism of action reverses and prevents death of injured cells Phase II ARPEGGIO trial fully enrolled Topline results to be presented at the World Stroke Congress, October 23, 2025 SOUTH SAN FRANCISCO, Calif., [...]
Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025
17/10/2025
Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals Results support the [...]
Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
17/10/2025
Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 ( ERBB2 )-mutant NSCLC were presented for the first [...]
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
17/10/2025
Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows triplet therapy with [...]
Protext Mobility, Inc. (OTC: TXTM) Announces Plans for Corporate Website Redesign and Investor Relations Suite to Enhance Transparency and Shareholder Engagement
17/10/2025
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM), an emerging leader in botanical-based biotechnology, today announced its strategic initiative to redesign its corporate website and develop [...]
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
17/10/2025
BRISBANE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]
WeightWatchers Launches RxFlexFund™, a New Employer Model for Expanding GLP-1 Coverage
17/10/2025
Provides a Differentiated Cost-Sharing Framework for GLP-1 Medications Paired With Clinical Oversight and Proven Behavior Change Support from WeightWatchers Clinic NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- WW [...]
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
17/10/2025
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment [...]
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
17/10/2025
WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
24/7 Market News- Kraig Labs Spider Silk Poised to Lead the Sustainable Textile Revolution
17/10/2025
Circular Fashion Gains Momentum DENVER, Oct. 17, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that, as the [...]
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
17/10/2025
BiomX believes that it has fully addressed the FDA’s queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clarifications on the [...]
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best [...]
CDT Equity Increases Bitcoin Holding
17/10/2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced the acquisition of 9.25648743 Bitcoin (“BTC”) for an aggregate [...]
Vystar’s Vytex® Cloud Bed-in-a-Box Available for Sale
17/10/2025
Luxuriously soft supportive com fort, resilience and breath ability Thicker mattress and the ultimate plush coverin g 6 sizes, 3 levels of softn ess World’s purest, naturally anti-microbial, odor-free and virtually [...]
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
17/10/2025
75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-up Immune activation observed in all [...]

Pages